Shanthi Mogali
Psychiatry, Addiction Medicine
Titles
- Assistant Professor of Psychiatry
- Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
- Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Education & Training
- Non Degree ProgramColumbia University, Addiction Psychiatry (2011)
- Non Degree ProgramEmory University School of Medicine, General Psychiatry
- MDMeharry Medical College (2005)
- BAFisk University
Additional Information
Board Certifications
- AB of Psychiatry & Neurology, Addiction Psychiatry (2012)
- AB of Psychiatry & Neurology, Psychiatry (2011)
Publications
- Jones JD, Mumtaz M, Vadhan NP, Martinez S, Pramanik S, Manubay J, Mogali S, Perez F, Castillo F, Kranzler HR, Comer SD. The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects. Behavioural Pharmacology 2022, 33: 255-265. PMID: 35438671, PMCID: PMC9149033, DOI: 10.1097/FBP.0000000000000671.
- Mogali S, Askalsky P, Madera G, Jones JD, Comer SD. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users. Pharmacology Biochemistry And Behavior 2021, 209: 173241. PMID: 34298029, PMCID: PMC8429209, DOI: 10.1016/j.pbb.2021.173241.
- Brandt L, Jones JD, Martinez S, Manubay JM, Mogali S, Ramey T, Levin FR, Comer SD. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug And Alcohol Dependence 2020, 208: 107859. PMID: 31980285, PMCID: PMC7063580, DOI: 10.1016/j.drugalcdep.2020.107859.
- Jones JD, Mumtaz M, Manubay JM, Mogali S, Sherwin E, Martinez S, Comer SD. Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. Pharmacology, Biochemistry, And Behavior 2019, 186: 172778. PMID: 31493434, PMCID: PMC6801039, DOI: 10.1016/j.pbb.2019.172778.
- Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer SD. The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal Of Psychoactive Drugs 2018, 50: 390-401. PMID: 30204554, PMCID: PMC6487639, DOI: 10.1080/02791072.2018.1508789.
- Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A. Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology, Biochemistry, And Behavior 2017, 163: 90-100. PMID: 29020601, PMCID: PMC5959043, DOI: 10.1016/j.pbb.2017.10.002.
- Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M, Comer SD. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug And Alcohol Dependence 2017, 179: 362-369. PMID: 28844013, DOI: 10.1016/j.drugalcdep.2017.06.033.
- Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 2017, 42: 1825-1832. PMID: 28393896, PMCID: PMC5520790, DOI: 10.1038/npp.2017.70.
- Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer SD. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Physiology & Behavior 2015, 159: 33-39. PMID: 26455893, PMCID: PMC5444321, DOI: 10.1016/j.physbeh.2015.10.006.
- Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addiction Biology 2015, 20: 784-98. PMID: 25060839, PMCID: PMC4305506, DOI: 10.1111/adb.12163.
- Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A. Baseline characteristics of patients predicting suitability for rapid naltrexone induction. The American Journal On Addictions / American Academy Of Psychiatrists In Alcoholism And Addictions 2015, 24: 258-264. PMID: 25907815, PMCID: PMC4496800, DOI: 10.1111/ajad.12180.
- Gudin JA, Mogali S, Jones JD, Comer SD. Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. Postgraduate Medicine 2013, 125: 115-130. PMID: 23933900, PMCID: PMC4057040, DOI: 10.3810/pgm.2013.07.2684.
- Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW. Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. Neuropsychopharmacology 2013, 38: 2427-2438. PMID: 23736314, PMCID: PMC3799062, DOI: 10.1038/npp.2013.143.
- Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 2013, 154: 1442-1448. PMID: 23707283, PMCID: PMC3770461, DOI: 10.1016/j.pain.2013.05.004.
- Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug And Alcohol Dependence 2012, 125: 8-18. PMID: 22857878, PMCID: PMC3454351, DOI: 10.1016/j.drugalcdep.2012.07.004.
- Mogali S, Darville K, Pratt LM. Ab initio analysis of lithium dimethylaminoborohydride. The Journal Of Organic Chemistry 2001, 66: 2368-73. PMID: 11281777, DOI: 10.1021/jo001600j.
Titles
- Assistant Professor of Psychiatry
- Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
- Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Education & Training
- Non Degree ProgramColumbia University, Addiction Psychiatry (2011)
- Non Degree ProgramEmory University School of Medicine, General Psychiatry
- MDMeharry Medical College (2005)
- BAFisk University
Additional Information
Board Certifications
- AB of Psychiatry & Neurology, Addiction Psychiatry (2012)
- AB of Psychiatry & Neurology, Psychiatry (2011)
Publications
- Jones JD, Mumtaz M, Vadhan NP, Martinez S, Pramanik S, Manubay J, Mogali S, Perez F, Castillo F, Kranzler HR, Comer SD. The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects. Behavioural Pharmacology 2022, 33: 255-265. PMID: 35438671, PMCID: PMC9149033, DOI: 10.1097/FBP.0000000000000671.
- Mogali S, Askalsky P, Madera G, Jones JD, Comer SD. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users. Pharmacology Biochemistry And Behavior 2021, 209: 173241. PMID: 34298029, PMCID: PMC8429209, DOI: 10.1016/j.pbb.2021.173241.
- Brandt L, Jones JD, Martinez S, Manubay JM, Mogali S, Ramey T, Levin FR, Comer SD. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug And Alcohol Dependence 2020, 208: 107859. PMID: 31980285, PMCID: PMC7063580, DOI: 10.1016/j.drugalcdep.2020.107859.
- Jones JD, Mumtaz M, Manubay JM, Mogali S, Sherwin E, Martinez S, Comer SD. Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. Pharmacology, Biochemistry, And Behavior 2019, 186: 172778. PMID: 31493434, PMCID: PMC6801039, DOI: 10.1016/j.pbb.2019.172778.
- Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer SD. The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal Of Psychoactive Drugs 2018, 50: 390-401. PMID: 30204554, PMCID: PMC6487639, DOI: 10.1080/02791072.2018.1508789.
- Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A. Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology, Biochemistry, And Behavior 2017, 163: 90-100. PMID: 29020601, PMCID: PMC5959043, DOI: 10.1016/j.pbb.2017.10.002.
- Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M, Comer SD. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug And Alcohol Dependence 2017, 179: 362-369. PMID: 28844013, DOI: 10.1016/j.drugalcdep.2017.06.033.
- Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 2017, 42: 1825-1832. PMID: 28393896, PMCID: PMC5520790, DOI: 10.1038/npp.2017.70.
- Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer SD. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Physiology & Behavior 2015, 159: 33-39. PMID: 26455893, PMCID: PMC5444321, DOI: 10.1016/j.physbeh.2015.10.006.
- Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addiction Biology 2015, 20: 784-98. PMID: 25060839, PMCID: PMC4305506, DOI: 10.1111/adb.12163.
- Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A. Baseline characteristics of patients predicting suitability for rapid naltrexone induction. The American Journal On Addictions / American Academy Of Psychiatrists In Alcoholism And Addictions 2015, 24: 258-264. PMID: 25907815, PMCID: PMC4496800, DOI: 10.1111/ajad.12180.
- Gudin JA, Mogali S, Jones JD, Comer SD. Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. Postgraduate Medicine 2013, 125: 115-130. PMID: 23933900, PMCID: PMC4057040, DOI: 10.3810/pgm.2013.07.2684.
- Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW. Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. Neuropsychopharmacology 2013, 38: 2427-2438. PMID: 23736314, PMCID: PMC3799062, DOI: 10.1038/npp.2013.143.
- Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 2013, 154: 1442-1448. PMID: 23707283, PMCID: PMC3770461, DOI: 10.1016/j.pain.2013.05.004.
- Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug And Alcohol Dependence 2012, 125: 8-18. PMID: 22857878, PMCID: PMC3454351, DOI: 10.1016/j.drugalcdep.2012.07.004.
- Mogali S, Darville K, Pratt LM. Ab initio analysis of lithium dimethylaminoborohydride. The Journal Of Organic Chemistry 2001, 66: 2368-73. PMID: 11281777, DOI: 10.1021/jo001600j.